Skip to main content
Log in

Medikamenteninduzierte Osteopathien

Medikamente, Pathogenese, Formen, Diagnostik, Prävention und Therapie

Drug-induced osteopathies

Drugs, pathogenesis, forms, diagnosis, prevention and therapy

  • CME Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Orthopäde Aims and scope Submit manuscript

Zusammenfassung

Eine Vielzahl unterschiedlicher Medikamente greift als „Nebenwirkung“ in den Knochenstoffwechsel und -umbau ein und verursacht Knochenschwund und Mineralisationsstörungen bis hin zu Osteonekrosen. Diese Formen der Knochenschädigung werden bisher als Arzneimittelnebenwirkung in Klinik und Praxis noch zu wenig beachtet und v. a. auch nicht mit den Patienten besprochen. Präventive Maßnahmen werden vor Einsatz des Medikamentes nicht bedacht, und selbst bei Auftreten der Knochenschäden werden therapeutische Strategien nur mangelhaft umgesetzt. Auch die Frakturheilung mit ihrem komplexen, phasenhaften Ablauf kann durch zahlreiche Medikamente sowohl negativ als auch positiv beeinflusst werden und bedarf einer Kontrolle. Vorschläge einer praxisnahen Vorsorge und Therapie der medikamenteninduzierten Osteopathien werden abschließend vorgestellt.

Abstract

A number of drugs can have “side effects” on bone metabolism and formation, causing bone atrophy, impaired mineralisation, as well as osteonecrosis. In both clinical and general practitioner settings, these forms of bone damage have been hitherto considered as adverse drug side effects and have received insufficient attention; moreover, they have not been the subject of patient information. Preventive measures are not instigated prior to initiation of medication and even after onset of bone damage, therapeutic strategies are poorly implemented. Even fracture healing with its complex, staged course can be both positively and negatively influenced by a number of drugs and these effects require monitoring. Recommendations regarding practical screening and therapy of drug-induced osteopathies are presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7
Abb. 8
Abb. 9
Abb. 10

Literatur

  1. Allport J (2008) Incidence and prevalence of medication-induced osteoporosis: evidence-based review. Curr Opin Rheumatol 20:435–441

    Article  CAS  PubMed  Google Scholar 

  2. Aspenberg P (2005) Drugs and fracture repair. Acta Orthop 76:741–748

    Article  PubMed  Google Scholar 

  3. Bartl R (2006) Antiosteoporotika. Wissenschaftliche Verlagsgesellschaft, Stuttgart

  4. Bartl R (2007) Antiepileptika-induzierte Osteopatie – Pathogenese, Prophylaxe, Früherkennung und Therapie. Dtsch Med Wochenschr 132:1475–1479

    Article  CAS  PubMed  Google Scholar 

  5. Bartl R (2008) Osteoporose – Prävention, Diagnostik, Therapie, 3. Aufl. Thieme, Stuttgart

  6. Bartl R, Frisch B, Tresckow E von, Bartl C (2007) Bisphosphonates in medical practice. Springer, Berlin

  7. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

    Article  CAS  PubMed  Google Scholar 

  8. Borderi M, Farneti B, Tampellini L et al (2002) HIV-1, HAART and bone metabolism. New Microbiol 25:375–384

    CAS  PubMed  Google Scholar 

  9. Brown T, Qaqish R (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20:2165–2174

    Article  PubMed  Google Scholar 

  10. Gage B, Birman-Deych E, Radford M et al (2006) Risk of osteoporotic fracture in elderly patients taking warfarin. Arch Intern Med 166:241–246

    Article  CAS  PubMed  Google Scholar 

  11. Kahn S, Haffner S, Heise M et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443

    Article  CAS  PubMed  Google Scholar 

  12. Knobel H, Guelar A, Vallecillo G et al (2001) Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 15:807–808

    Article  CAS  PubMed  Google Scholar 

  13. Marcus R (2008) Osteoporosis. Academic Press, San Diego

  14. Mezuk B, Eaton W, Golden S (2008) Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos Int 19:1–12

    Article  CAS  PubMed  Google Scholar 

  15. Minkowitz B, Boskey A, Lane J et al (1991) Effects of propranolol on bone metabolism in the rat. J Orthop Res 9:869–875

    Article  CAS  PubMed  Google Scholar 

  16. Mori S (2003) Fracture healing with anti-resorptive agents. J Musculoskelet Neuronal Interact 3:314–316

    CAS  PubMed  Google Scholar 

  17. Pack AM, Olarte LS, Morrell MJ et al (2003) Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 4:169–174

    Article  PubMed  Google Scholar 

  18. Petty SJ, O’Brian TJ, Wark JD (2007) Antiepileptic medication and bone health. Osteoporos Int 18:129–142

    Article  CAS  PubMed  Google Scholar 

  19. Pilon D, Castilloux AM, Dorais M et al (2004) Oral anticoagulants and the risk of osteoporotic fractures among elderly. Pharmacoepidemiol Drug Saf 13:289–294

    Article  CAS  PubMed  Google Scholar 

  20. Richy F, Bousquet J, Eherlich G et al (2003) Inhaled corticosteroid effects on bone in asthmatic and COPD patients: a quantitative systematic study. Osteoporos Int 14:179–190

    CAS  PubMed  Google Scholar 

  21. Saag K, Emkey R, Schnitzer T et al (1998) Alendronate for the treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292–299

    Article  CAS  PubMed  Google Scholar 

  22. Smith I, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431–2442

    Article  CAS  PubMed  Google Scholar 

  23. Smith M, Eastham J, Gleason D et al (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008–2012

    Article  CAS  PubMed  Google Scholar 

  24. Tebas P, Powderly W, Claxton S et al (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiviral therapy. AIDS 14:F63–F67

    Article  CAS  PubMed  Google Scholar 

  25. Van Staa T, Leufkens H, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787

    Article  Google Scholar 

  26. Vestergaard P (2005) Epilepsy, osteoporosis and fracture risk – a meta-analysis. Acta Neurol Scand 112:277–286

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R. Bartl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bartl, R., Bartl, C. & Gradinger, R. Medikamenteninduzierte Osteopathien. Orthopäde 38, 1245–1261 (2009). https://doi.org/10.1007/s00132-009-1436-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00132-009-1436-4

Schlüsselwörter

Keywords

Navigation